blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2150545

EP2150545 - N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.02.2014
Database last updated on 28.09.2024
Most recent event   Tooltip28.02.2014Application deemed to be withdrawnpublished on 02.04.2014  [2014/14]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2010/06]
Inventor(s)01 / BARLAAM, Bernard, Christophe
AstraZeneca Pharma Z.I. la Pompelle BP1050 Chemin de Vrilly
F-51689 Reims Cedex 2 / FR
02 / DUCRAY, Richard
AstraZeneca Pharma Z.I. la Pompelle BP1050 Chemin de Vrilly
F-51689 Reims Cedex 2 / FR
 [2010/06]
Application number, filing date08737220.725.04.2008
[2010/06]
WO2008GB50295
Priority number, dateEP2007030100127.04.2007         Original published format: EP 07301001
EP2007030100227.04.2007         Original published format: EP 07301002
[2010/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008132505
Date:06.11.2008
Language:EN
[2008/45]
Type: A1 Application with search report 
No.:EP2150545
Date:10.02.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 06.11.2008 takes the place of the publication of the European patent application.
[2010/06]
Search report(s)International search report - published on:EP06.11.2008
ClassificationIPC:C07D401/12, C07D403/12, A61K31/506, A61P35/00
[2010/06]
CPC:
C07D401/12 (EP,KR,US); C07D403/12 (KR); A61K31/506 (KR);
A61P35/00 (EP); A61P43/00 (EP); C07D239/50 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/06]
Extension statesAL27.11.2009
BA27.11.2009
MK27.11.2009
RS27.11.2009
TitleGerman:Ný-(PHENYL)-N-(MORPHOLIN-4-YLPYRIDIN-2-YL)PYRIMIDIN-2,4-DIAMINDERIVATE ALS INHIBITOREN VON EPHB4-KINASE ZUR BEHANDLUNG PROLIFERATIVER LEIDEN[2010/06]
English:N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS[2010/06]
French:NOUVEAUX DÉRIVÉS DE N' - (PHÉNYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINEPYRIMIDINE EN TANT QU'INHIBITEURS DE EPHB4 KINASE POUR LE TRAITEMENT D'ÉTATS PROLIFÉRATIFS[2010/06]
Entry into regional phase27.11.2009National basic fee paid 
27.11.2009Designation fee(s) paid 
27.11.2009Examination fee paid 
Examination procedure27.11.2009Examination requested  [2010/06]
01.11.2013Application deemed to be withdrawn, date of legal effect  [2014/14]
27.11.2013Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2014/14]
Fees paidRenewal fee
03.05.2010Renewal fee patent year 03
02.05.2011Renewal fee patent year 04
02.05.2012Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.04.201306   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2006059234  (NOVARTIS AG [CH], et al) [A] 1-13 * the whole document *;
 [A]WO2007028445  (GLAXO GROUP LTD [GB], et al) [A] 1-13 * the whole document *;
 [PA]WO2007085833  (ASTRAZENECA AB [SE], et al) [PA] 1-13 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.